|
EMN30 |
Phase III |
Teclistamab + Lenalidomide and Teclistamab Mono versus Lenalidomide Mono in NDMM as Maintenance Therapy Following Autologous Stem Cell Transplantation |
|
DSMM XVIII |
Phase III |
Randomisierte Phase 3-Studie zur Untersuchung einer Erhaltungstherapie mit Iberdomid versus Iberdomid plus Isatuximab nach autologer hämatopoetischer Blutstammzelltrans-plantation für Patienten mit neudiagnostiziertem Multiplem Myelom Eudract Nr. 2023-507402-13-00 |
|
IM048-022 |
Phase III |
A Phase 3, Two-stage, Randomized, Multi-center, Controlled, Open-label Study Comparing Iberdomide Maintenance to Lenalidomide Maintenance Therapy After Autologous Stem Cell Transplantation (ASCT) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) (EXCALIBER-Maintenance) |
|
CA057-008
|
Phase III |
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma |
|
MAGNETISMM-32 |
Phase III |
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide) |
Menü
